首頁 > 市場調查報告書 > 醫療設備

體外診斷生技設備

市場調查報告書

商品編碼

1439913

ELISA - 全球市場考量、競爭格局、市場預測 (2030)

Enzyme Linked Immunosorbent Assay (Elisa) - Market Insights, Competitive Landscape, and Market Forecast - 2030

出版日期: 按訂單生產 | 出版商:

DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄圖表

全球 ELISA 市場規模預計到 2023 年將達到 53.4 億美元，到 2030 年將達到 75.8 億美元，2024-2030 年預測期間複合年增長率為 6.07%。Masu。該市場的推動因素包括愛滋病毒、結核病、瘧疾和乙型肝炎等傳染病的流行、酶聯免疫吸附試驗(ELISA) 在藥物濫用檢測中的廣泛應用，以及酶聯免疫吸附試驗(ELISA) 的準確性、便攜性、可用性和易用性的提高，以檢測最終結果。由於行業關注度不斷提高等因素，該市場預計將蓬勃發展，並預計在預測期內（2024-2030年）收入將出現顯著增長。

ELISA市場動態

ELISA 市場的顯著驅動因素之一是全球性傳染感染數量的不斷增加。例如，根據世界衛生組織 (WHO) (2022) 的數據，全球每天約有 100 萬人感染性傳染病。此外，根據相同的數據，預計2020年將記錄約1.29億例衣原體病例、710萬例梅毒病例、8,200萬例淋病病例和1.56億例滴蟲病例。

影響全球數百萬人的各種類型的癌症也是 ELISA 市場的驅動因素之一。例如，根據世界衛生組織 (WHO) (2022) 的數據，2020 年約有 226 萬乳癌病例、221 萬肺癌病例和 193 萬大腸癌病例。此外，提高成年人口對肺癌、乳癌和攝護腺癌等癌症的認識，以及醫生每年推薦對這些疾病進行生物標記檢測，也將加速 ELISA 市場的發展。

ELISA 正在擴大其在藥物濫用檢測中的應用，這可能會增加其需求並對 ELISA 市場的成長產生積極影響。例如，根據聯合國毒品和犯罪問題辦公室 (UNODC) (2022) 的數據，去年全球約有 2.75 億人吸毒，超過 3,600 萬人患有吸毒障礙。許多藥物被濫用，包括四氫大麻酚（THC）、美沙酮、鴉片類藥物、苯二氮平類藥物等，而ELISA可以在毛髮、血液、尿液、口腔液、血清、血漿等各種生物標本中檢測到這些藥物的存在。的藥物。

此外，製藥和生技產業的持續研發再次帶動了 ELISA 市場的成長。

然而，替代產品的可用性以及與 ELISA 相關的限制可能會限制 ELISA 市場的成長。

在 COVID-19 期間，由於患者數量的增加導致對診斷工具和技術的需求增加，ELISA 市場呈現邊際增長。由於COVID-19大流行，FDA批准了大量基於ELISA的診斷試劑盒供緊急使用，這導致了敏感且可靠的基於ELISA的診斷試劑盒的開發，用於檢測Sars COV-2。因此，它對ELISA市場產生積極影響。大流行情況對 2024-2030 年預測期內的 ELISA 市場有正面影響。

ELISA市場區隔分析

在 ELISA 市場的產品類型細分市場中，試劑盒和試劑細分市場預計將出現顯著的市場成長。

ELISA 試劑盒和試劑廣泛用於快速檢測和定量針對細菌、病毒和其他抗原的抗體。使用 ELISA 試劑盒和試劑可以檢測數百種蛋白質和分子，包括細胞激素、生長因子、傳染病、糖尿病和腫瘤標記、藥物和小分子。

這些是有效、快速、方便和準確的研究工具，用於檢測和量化培養物和樣品中感興趣的目標。

因此，考慮到對該產品類型不斷增長的需求，市場上正在推出許多新產品。 2022年9月，J Mitra宣佈推出第四代基於Elisa的HCV檢測試劑盒，HCV Gen 4 Ag & Ab Microlisa。該試劑盒專門用於篩檢捐血、識別和消除受感染的血液以及丙型肝炎的臨床診斷測試。

本報告研究和分析了全球 ELISA 市場，提供市場規模和預測、驅動因素和挑戰、公司和產品概況等。

ELISA 市場驅動因素
- 傳染病流行
- 藥物濫用檢測中對 ELISA 的需求不斷增加
- 擴大 ELISA 在腫瘤的應用
ELISA市場的限制與挑戰
- 替代產品的可用性
- 與 ELISA 相關的限制
ELISA 市場機會
- 醫療支出增加
- 對經濟高效的診斷工具的需求不斷增加

第五章 ELISA 市場波特五力分析

第六章COVID-19對ELISA市場的影響分析

第七章 ELISA市場佈局

依產品類型
- 試劑盒/試劑
- ELISA系統
- 其他
依用途
- 愛滋病毒
- 妊娠測試
- 新冠肺炎 (COVID-19)
按最終用戶
- 醫院、診斷實驗室
- 製藥和生物技術產業
按地區
- 北美
- 歐洲
- 亞太地區
- 其他領域

第 8 章 ELISA 市場：全球公司佔有率分析 - 3 至 5 家主要公司

第9章 ELISA市場公司及產品概況

Abbott
Erba Mannheim
Synbiotik
F. Hoffmann-La Roche Ltd
Maccura Biotechnology Co.
DiaSorin
Thermo Fisher Scientific
PerkinElmer Inc.
Diatron
Trivitron Healthcare
Werfen
BD
ALPCO
Quidel Corporation
Agilent
InBios International, Inc
Awareness Technology, Inc.
Elabscience Biotechnology Inc
J. Mitra & Co. Pvt. Ltd.
Rayto Life and Analytical Sciences Co., Ltd.

第10章KOL觀看次數

第 11 章專案方法

第 12 章關於 DelveInsight

第 13 章免責聲明與聯絡我們

簡介目錄圖表

Product Code: DIMDCL0591

ELISA MARKET BY PRODUCT TYPE (KITS AND REAGENTS, ELISA SYSTEMS, AND OTHERS), BY APPLICATION (HIV, PREGNANCY TESTING, COVID-19, AND OTHERS), BY END-USER (HOSPITALS AND DIAGNOSTIC LABS, PHARMACEUTICAL AND BIOTECH INDUSTRIES, AND OTHERS), BY GEOGRAPHY IS ESTIMATED TO REGISTER GROWTH AT A REMARKABLE CAGR FORECAST DURING 2024-2030 OWING TO SURGE IN PREVALENCE OF INFECTIOUS DISEASES AND CONTINUOUS RESEARCH AND DEVELOPMENT ACTIVITIES HAPPENING IN PHARMACEUTICAL AND BIOTECH INDUSTRIES.

The global ELISA market was valued at USD 5.34 billion in 2023, growing at a CAGR of 6.07% during the forecast period from 2024 to 2030 to reach USD 7.58 billion by 2030. The ELISA market is slated to witness prosperity owing to factors such as growing prevalence of infectious diseases such as HIV, tuberculosis, malaria, and hepatitis B among others, growing application of ELISA for drug abuse testing, and the growing focus on improving the accuracy, portability, affordability, and usability of ELISA for end users are further expected to result in the appreciable revenue growth in the ELISA Market during the forecast period (2024-2030).

ELISA MARKET DYNAMICS:

One of the noteworthy drivers of the ELISA market is the elevation in cases of sexually transmitted diseases worldwide. For instance, according to World Health Organization (WHO) 2022, worldwide around 1 million people acquire STDs every day. Also, as per the same source, it was estimated that there were around 129 million cases of chlamydia, 7.1 million cases of syphilis, 82 million cases of gonorrhea, and around 156 million cases of trichomoniasis recorded in 2020.

The different cancer types affecting millions of people worldwide is another driver for ELISA market. For instance as per the World Health Organization (WHO) 2022, there were around 2.26 million cases of breast cancer, 2.21 million cases of lung cancer 1.93 million cases of colon and rectal cancer, recorded in 2020. Also, the rising awareness on cancer such as lung, breast, and prostate cancer amongst the adult population as well as recommendation of annual tests of biomarkers of these diseases by doctors is going to accelerate the market of ELISA.

The rising application of ELISA in drug abuse testing is likely to increase its demand, thus positively impacting the market growth for ELISA market. For instance, according United Nations Office on Drugs and Crime (UNODC) 2022, around 275 million people used drugs worldwide in the last year, while over 36 million people suffered from drug use disorders. The number of drugs including Tetrahydrocannabinol (THC), methadone, opioids, benzodiazepines, and others are abused by many and ELISA is capable of detecting the presence of these drugs in various biological specimens such as hair, blood, urine, oral fluid, serum, plasma, and others.

Also, the continuous research and development across pharmaceutical and biotechnology industries is again leading towards the growth in ELISA market.

However, the availability of alternative products and limitations associated with ELISA may act as restraining factors to the ELISA market growth.

During the period of COVID-19 infection, the ELISA market witnessed slight growth owing to increased number of cases of leading to increased need of diagnostic tools and technologies. The COVID-19 pandemic resulted in vast FDA approvals of ELISA based diagnostic kits under emergency use status which further led to the development of sensitive and reliable ELISA based diagnostic kits for the detection of Sars COV-2. Thus, positively impacting the ELISA market. The pandemic scenario has been uplifting for the ELISA market during the forecast period from 2024-2030.

ELISA MARKET SEGMENT ANALYSIS:

ELISA Market by Product Type (Kits and Reagents, Elisa Systems, and Others), Application (HIV, Pregnancy Testing, COVID- 19, and Others), End-User (Hospitals, Biotechnology Industries, Pharmaceutical Industries and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Based on the product type segment of the ELISA market, the kits and reagents segment is going to register a significant market growth.

ELISA kits and reagents are widely utilized for the rapid detection and quantification of antibodies against bacteria, viruses, as well as other material antigens. The hundreds of different proteins and molecules including cytokines, growth factors, markers for infectious diseases, diabetes and tumor, drugs and small molecules can be detected through ELISA kits and reagents.

These are effective, quick, convenient, and accurate research tool for the detection and quantitation of targets of interest in cultures and samples.

Therefore, considering the growing demand for this product type, numerous new products are being launched in the market. In September 2022, J Mitra announced the launch of their 4th Generation Elisa-based HCV Test-the HCV Gen 4 Ag & Ab Microlisa. The kit is particularly intended for screening blood donations to identify and eliminate the infected units of blood and for clinical diagnostic testing of Hepatitis C.

Therefore, considering the advantages and applications associated with ELISA kits and reagents and their growing popularity among end users, this product category is expected to generate considerable revenue thereby pushing the overall growth of the global ELISA market during the forecast period.

NORTH AMERICA IS EXPECTED TO DOMINATE THE OVERALL ELISA MARKET:

Among all the regions, North America is expected to lead in revenue generation in the global ELISA market. This can be ascribed to the presence of large patient pool associated with infectious diseases, government support, high consumer awareness regarding new market launches and a highly potent market in terms of product development and launches, and the local presence of key market players among other factors in the region.

The increasing prevalence of infectious diseases such as malaria, tuberculosis, hepatitis B, and other are likely to accelerate the growth of ELISA market. As per Centers for Diseases Control and Prevention 2022, around 7,860 new cases of tuberculosis were reported in the US in 2022. According to CDC 2022, each year nearly 2,000 cases of malaria are reported in the US.

Moreover, increasing number of blood donations and blood transfusions in the region necessitates the use of ELISA kits for the detection of hepatitis B and other infections in order to avoid the risk of transfusion of infected blood in patients. For instance, as per the Centers for Disease Control and Prevention 2020, there are around 13.2 million blood donors in the United States, resulting in a total of 17.2 million transfused blood product units per year.

One of the prominent factors supporting the growth of the North America ELISA market is the extensive use of ELISA in the detection of tumor markers indicating cancer development. As per American Cancer Society 2022, it has been estimated that around 1.9 million new cancer cases will be diagnosed in the US in 2022. Also, according to Centers for Disease Control and Prevention (CDC) 2022, around 1,752,735 new cancer cases were reported in 2019 in the US.

Therefore, the presence of large number of patients coupled with the increasing focus of manufacturers on launching new products in the market is expected to bolster the growth of the ELISA market in the United States during the forecast period.

ELISA MARKET KEY PLAYERS:

Some of the key market players operating in the ELISA market includes Abbott, F. Hoffmann-La Roche Ltd, Erba Mannheim, Synbiotik, Maccura Biotechnology Co., Ltd., Thermo Fisher Scientific, DiaSorin, PerkinElmer Inc., Diatron, Werfen, ALPCO, Agilent, InBios International Inc., Awareness Technology Inc., Elabscience Biotechnology Inc., J. Mitra & Co. Pvt. Ltd., Rayto Life and Analytical Sciences Co.,Ltd., BD, Trivitron Healthcare, and others.

RECENT DEVELOPMENTAL ACTIVITIES IN ELISA MARKET:

In February 2022, Agilent Technologies Inc. announced the launch of the Agilent Dako SARS-CoV-2 IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit for the qualitative detection of immunoglobulin G (IgG) antibodies to SARS-CoV-2 in human serum or plasma

In April 2020, ERBA Mannheim announced the launch of its CE ErbaLisa® COVID-19 ELISA kits

In November 2020, Enzo announced the launch of portable microplate reader for its elisa and other assay kits

KEY TAKEAWAYS FROM THE ELISA MARKET REPORT STUDY

Market size analysis for current ELISA Market size (2023), and market forecast for 5 years (2024-2030)
The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the ELISA market.
Top key product/services/technology developments, mergers, acquisitions, partnerships, joint ventures happened for last 3 years
Key companies dominating the global ELISA market.
Various opportunities available for the other competitor in the ELISA market space.
What are the top performing segments in 2023? How these segments will perform in 2030.
Which is the top-performing regions and countries in the current ELISA market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for ELISA market growth in the coming future?

TARGET AUDIENCE WHO CAN BE BENEFITED FROM THIS ELISA MARKET REPORT STUDY

ELISA products providers
Research organizations and consulting companies
ELISA -related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and Traders dealing in ELISA
Various end users who want to know more about the ELISA market and latest technological developments in the ELISA market.

FREQUENTLY ASKED QUESTIONS FOR ELISA MARKET:

1. What is ELISA?

ELISA is a type of plate-based diagnostic assay that is designed for detecting and quantifying soluble substances such as peptides, proteins, antibodies, and hormones based on specific reaction between antigen-antibody and thus helping in disease diagnosis.

2. What is the market for the global ELISA?

The global ELISA market was valued at USD 5.34 billion in 2023, growing at a CAGR of 6.07% during the forecast period from 2024 to 2030 to reach USD 7.58 billion by 2030.

3. What are the drivers for the global ELISA market?

The ELISA market is slated to witness prosperity owing to factors such as growing prevalence of infectious and other chronic diseases such as cancer, HIV, and others, increasing research and development activities across biotech and pharmaceutical industries, increasing healthcare expenditure, and the growing focus on improving the accuracy, affordability, portability, and usability of ELISA for end users are further expected to result in the appreciable revenue growth in the ELISA market during the forecast period (2024-2030).

4. Who are the key players operating in the global ELISA market?

5. Which region has the highest share in the ELISA market?

North America is expected to dominate the overall ELISA Market during the forecast period, 2024 to 2030. This can be ascribed to the presence of large patient pool associated with infectious and other diseases, high consumer awareness regarding new market launches, government support, and a highly potent market in terms of product development and launches, and the local presence of key market players among other factors in the region.

1. ELISA Market Report Introduction

2. ELISA Market Executive Summary

2.1 Scope of the Study
2.2 Market at Glance
2.3 Competitive Assessment
2.4 Financial Benchmarking

3. Regulatory Analysis

3.1 The United States
3.2 Europe
3.3 Japan
3.4 China

4. ELISA Market Key Factors Analysis

4.1 ELISA Market Drivers
- 4.1.1 Increasing prevalence of infectious diseases
- 4.1.2 Rising demand of ELISA for drug abuse testing
- 4.1.3 Expanding the applications of ELISA in oncology
4.2 ELISA Market Restraints and Challenges
- 4.2.1 Availability of alternative products
- 4.2.2 Limitations associated with ELISA
4.3 ELISA Market Opportunities
- 4.3.1 Increasing healthcare expenditure
- 4.3.2 Increasing demand for cost effective diagnostic tools

5. ELISA Market Porter's Five Forces Analysis

5.1 Bargaining Power of Suppliers
5.2 Bargaining Power of Consumers
5.3 Threat of New Entrants
5.4 Threat of Substitutes
5.5 Competitive Rivalry

6. COVID-19 Impact Analysis on ELISA Market

7. ELISA Market Layout

7.1 By Product Type
- 7.1.1 Kits and Reagents
- 7.1.2 ELISA Systems
- 7.1.3 Others
7.2 By Application
- 7.2.1 HIV
- 7.2.2 Pregnancy Testing
- 7.2.3 COVID-19
- 7.2.4 Others
7.3 By End-users
- 7.3.1 Hospitals and Diagnostic Labs
- 7.3.2 Pharmaceutical & Biotech Industries
- 7.3.3 Others
7.4 By Geography
- 7.4.1 North America
  - 7.4.1.1 United States ELISA Market in USD million (2021-2030)
  - 7.4.1.2 Canada ELISA Market in USD million (2021-2030)
  - 7.4.1.3 Mexico ELISA Market in USD million (2021-2030)
- 7.4.2 Europe
  - 7.4.2.1 France ELISA Market in USD million (2021-2030)
  - 7.4.2.2 Germany ELISA Market in USD million (2021-2030)
  - 7.4.2.3 United Kingdom ELISA Market in USD million (2021-2030)
  - 7.4.2.4 Italy ELISA Market in USD million (2021-2030)
  - 7.4.2.5 Spain ELISA Market in USD million (2021-2030)
  - 7.4.2.6 Rest of Europe ELISA Market in USD million (2021-2030)
- 7.4.3 Asia-Pacific
  - 7.4.3.1 China ELISA Market in USD million (2021-2030)
  - 7.4.3.2 Japan ELISA Market in USD million (2021-2030)
  - 7.4.3.3 India ELISA Market in USD million (2021-2030)
  - 7.4.3.4 Australia ELISA Market in USD million (2021-2030)
  - 7.4.3.5 South Korea ELISA Market in USD million (2021-2030)
  - 7.4.3.6 Rest of Asia Pacific ELISA Market in USD million (2021-2030)
- 7.4.4 Rest of the World (RoW)
  - 7.4.4.1. Middle East ELISA Market in USD million (2021-2030)
  - 7.4.4.2 Africa ELISA Market in USD million (2021-2030)
  - 7.4.4.3 South America ELISA Market in USD million (2021-2030)

8. ELISA Market Global Company Share Analysis - Key 3-5 Companies

9. ELISA Market Company and Product Profiles

9.1 Abbott
- 9.1.1. Company Overview
- 9.1.2. Company Snapshot
- 9.1.3. Financial Overview
- 9.1.4. Product Listing
- 9.1.5. Entropy
9.2 Erba Mannheim
- 9.2.1. Company Overview
- 9.2.2. Company Snapshot
- 9.2.3. Financial Overview
- 9.2.4. Product Listing
- 9.2.5. Entropy
9.3 Synbiotik
- 9.3.1. Company Overview
- 9.3.2. Company Snapshot
- 9.3.3. Financial Overview
- 9.3.4. Product Listing
- 9.3.5. Entropy
9.4 F. Hoffmann-La Roche Ltd
- 9.4.1. Company Overview
- 9.4.2. Company Snapshot
- 9.4.3. Financial Overview
- 9.4.4. Product Listing
- 9.4.5. Entropy
9.5 Maccura Biotechnology Co.
- 9.5.1. Company Overview
- 9.5.2. Company Snapshot
- 9.5.3. Financial Overview
- 9.5.4. Product Listing
- 9.5.5. Entropy
9.6 DiaSorin
- 9.6.1. Company Overview
- 9.6.2. Company Snapshot
- 9.6.3. Financial Overview
- 9.6.4. Product Listing
- 9.6.5. Entropy
9.7 Thermo Fisher Scientific
- 9.7.1. Company Overview
- 9.7.2. Company Snapshot
- 9.7.3. Financial Overview
- 9.7.4. Product Listing
- 9.7.5. Entropy
9.8 PerkinElmer Inc.
- 9.8.1. Company Overview
- 9.8.2. Company Snapshot
- 9.8.3. Financial Overview
- 9.8.4. Product Listing
- 9.8.5. Entropy
9.9 Diatron
- 9.9.1. Company Overview
- 9.9.2. Company Snapshot
- 9.9.3. Financial Overview
- 9.9.4. Product Listing
- 9.9.5. Entropy
9.10 Trivitron Healthcare
- 9.10.1. Company Overview
- 9.10.2. Company Snapshot
- 9.10.3. Financial Overview
- 9.10.4. Product Listing
- 9.10.5. Entropy
9.11 Werfen
- 9.11.1. Company Overview
- 9.11.2. Company Snapshot
- 9.11.3. Financial Overview
- 9.11.4. Product Listing
- 9.11.5. Entropy
9.12 BD
- 9.12.1. Company Overview
- 9.12.2. Company Snapshot
- 9.12.3. Financial Overview
- 9.12.4. Product Listing
- 9.12.5. Entropy
9.13 ALPCO
- 9.13.1. Company Overview
- 9.13.2. Company Snapshot
- 9.13.3. Financial Overview
- 9.13.4. Product Listing
- 9.13.5. Entropy
9.14 Quidel Corporation
- 9.14.1. Company Overview
- 9.14.2. Company Snapshot
- 9.14.3. Financial Overview
- 9.14.4. Product Listing
- 9.14.5. Entropy
9.15 Agilent
- 9.15.1. Company Overview
- 9.15.2. Company Snapshot
- 9.15.3. Financial Overview
- 9.15.4. Product Listing
- 9.15.5. Entropy
9.16 InBios International, Inc
- 9.16.1. Company Overview
- 9.16.2. Company Snapshot
- 9.16.3. Financial Overview
- 9.16.4. Product Listing
- 9.16.5. Entropy
9.17 Awareness Technology, Inc.
- 9.17.1. Company Overview
- 9.17.2. Company Snapshot
- 9.17.3. Financial Overview
- 9.17.4. Product Listing
- 9.17.5. Entropy
9.18 Elabscience Biotechnology Inc
- 9.18.1. Company Overview
- 9.18.2. Company Snapshot
- 9.18.3. Financial Overview
- 9.18.4. Product Listing
- 9.18.5. Entropy
9.19 J. Mitra & Co. Pvt. Ltd.
- 9.19.1. Company Overview
- 9.19.2. Company Snapshot
- 9.19.3. Financial Overview
- 9.19.4. Product Listing
- 9.19.5. Entropy
9.20 Rayto Life and Analytical Sciences Co.,Ltd.
- 9.20.1. Company Overview
- 9.20.2. Company Snapshot
- 9.20.3. Financial Overview
- 9.20.4. Product Listing
- 9.20.5. Entropy